نتایج جستجو برای: hemolytic uremic syndrome

تعداد نتایج: 636518  

Journal: :BMC Clinical Pharmacology 2006
Issa Dahabreh George Tsoutsos Dimitrios Tseligas Dimitrios Janinis

BACKGROUND Oxaliplatin is a platinum derivative, which is used in the treatment of colorectal cancer. A small number of oxaliplatin-related hemolytic and/or thrombocytopenic reactions have been reported. We present a case of hemolytic-uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin. CASE PRESENTATION A 52-year-old...

2011
Daniel Patschan Peter Korsten Arne Behlau Radovan Vasko Malte Heeg Nadera Sweiss Gerhard A Müller Michael Koziolek

INTRODUCTION Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome is a life-threatening condition with various etiopathogeneses. Without therapy approximately 90% of all patients die from the disease. CASE PRESENTATION We report the case of a 17-year-old Caucasian woman with widespread hematomas and headache. Due to hemolytic anemia, thrombocytopenia, and schistocytosis, thrombotic t...

2014
David Kavanagh Shreya Raman Neil S. Sheerin

Hemolytic uremic syndrome (HUS) is a disease characterized by hemolysis, thrombocytopenia, and acute kidney injury, although other organs may be involved. Most cases are due to infection with Shiga toxin-producing Escherichia coli (STEC). Early identification and initiation of best supportive care, with microbiological input to identify the pathogen, result in a favorable outcome in most patien...

2017
Rafael Alonso Valente Giannina Elena García Rodríguez Yanina García Marcote Manuel Fidalgo Díaz Vanesa Becerra Mosquera Daniel Novoa García Teresa Cordal Martínez Cándido Díaz Rodríguez

BACKGROUND Atypical hemolytic-uremic syndrome is caused by a thrombotic microangiopathy and manifests itself with hemolytic anemia, thrombocytopenia, and organ ischemia. Its etiology is a mutation affecting the genes encoding for proteins of the complement system. Early treatment with eculizumab (8.6 months from the moment of presentation), a humanized monoclonal antibody against complement, is...

Journal: :American journal of kidney diseases : the official journal of the National Kidney Foundation 2002
Roland B Walter Markus Joerger Bernhard C Pestalozzi

BACKGROUND Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported. METHODS A case is presented of a 45-year-old woman on prolonged gemcitabine treatment for ovarian cancer who developed HUS and recovered after drug discontinuation. A mini-review of the literature based on a MEDLINE search follows. RESULTS Including our own...

Journal: :Current Opinion in Nephrology and Hypertension 2012

Journal: :Indian Journal of Critical Care Medicine 2017

2012
Seyed-Ali Sadjadi Pavan Annamaraju

BACKGROUND Gemcitabine is frequently used for the treatment of many cancers. Not infrequently it leads to development of hemolytic uremic syndrome, presenting with hemolytic anemia, acute kidney injury and occasionally peripheral edema, livedo reticularis and digital necrosis. CASE REPORT A 78 year old man with non-small cell lung cancer developed uremic syndrome following treatment with mult...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید